Arkolith/Insider Trading/TLX/Form 4

Behrenbruch Christian

MD & Group CEO, DirectorTelix Pharmaceuticals Ltd (TLX) · full profile →Form 4 · filed May 6, 2026
Net Buying
Open-Market Buys
$997K
Open-Market Sells
$0
Net Open-Market Flow
$997K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 29, 2026Buy(P)33K$14.87$497K20.7M
Apr 28, 2026Buy(P)35K$14.48$500K20.7M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-031608) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML